.png){kind=icon}
.png){kind=icon}
Return
NCCN: Continuing Education
.png){kind=icon}
OA
AI
DOI：10.6004/jnccn.2020.0017.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic provide recommendations for genetic testing and counseling for hereditary cancer syndromes, and risk management recommendations for patients who are diagnosed with syndromes associated with an increased risk of these cancers. The NCCN panel meets at least annually to review comments, examine relevant new data, and reevaluate and update recommendations. These NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding criteria for high-penetrance genes associated with breast and ovarian cancer beyond BRCA1/2, pancreas screening and genes associated with pancreatic cancer, genetic testing for the purpose of systemic therapy decision-making, and testing for people with Ashkenazi Jewish ancestry.
Keywords:
CANCER PREDISPOSITION GENES
FAMILIAL PANCREATIC-CANCER
HEREDITARY BREAST
GERMLINE MUTATIONS
RISK-ASSESSMENT
CLONAL HEMATOPOIESIS
MULTIGENE PANELS
OPEN-LABEL
BRCA2
PREVALENCE
Journal
J
IF:
16.4
Papers:
2.8K
Citations:
1.5W
Organization
View more organizations